modelCollagen
Extends from Pharmacolibrary.Drugs.ATC.G.G04BX11.
Information
| name: | Collagen | |
| ATC code: | G04BX11 | route: | injection |
| compartments: | 1 | |
| dosage: | 1 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Collagen is a naturally occurring protein that forms the primary structural component of connective tissues in the body. Pharmaceutical or supplemental collagen preparations have been investigated or used for tissue regeneration, wound healing, cosmetic purposes, and, under the ATC code G04BX11, as a urogynecological agent for the treatment of stress urinary incontinence. As of now, collagen-based drugs are used in specific clinical settings but are not routine systemic therapeutics, and products may vary widely in formulation.
Pharmacokinetics
No published peer-reviewed pharmacokinetic parameters available for medicinal collagen (G04BX11) in humans, as it is a large protein often used locally (e.g., injectable bulking agent); systemic absorption and related PK properties are negligible or not studied for these therapeutics.
References
Stratford, R, et al., & Ponnapakkam, T (2014). Pharmacokinetics in rats of a long-acting human parathyroid hormone-collagen binding domain peptide construct. Journal of pharmaceutical sciences 103(2) 768–775. DOI:10.1002/jps.23843 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24399637
Lon, HK, et al., & Jusko, WJ (2013). Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. Journal of pharmacokinetics and pharmacodynamics 40(6) 701–712. DOI:10.1007/s10928-013-9341-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24233383
Kalashnikova, I, et al., & Kim, T (2020). Ceria-based nanotheranostic agent for rheumatoid arthritis. Theranostics 10(26) 11863–11880. DOI:10.7150/thno.49069 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33204316
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)